VAERS 2021 Database www.vaers.hhs.gov

Main Page | All 2021 Deaths | Videos
VAERS Updated: 11/12/2021
** VAERS DATABASE Last updated: November 12, 2021**
PLEASE CHECK BACK SOON
Download the files above while you wait.







Manufacturers

Total Manufacturer
46,870MODERNA
532GLAXOSMITHKLINE BIOLOGICALS
353PFIZER\BIONTECH
231MERCK & CO. INC.
221UNKNOWN MANUFACTURER
62SEQIRUS, INC.
25DYNAVAX TECHNOLOGIES CORPORATION
13EMERGENT BIOSOLUTIONS
12SANOFI PASTEUR
9NOVARTIS VACCINES AND DIAGNOSTICS
5PFIZER\WYETH
5PAXVAX
2TEVA PHARMACEUTICALS
2PROTEIN SCIENCES CORPORATION
1BERNA BIOTECH, LTD.
1INTERCELL AG
1CSL LIMITED

COVID19 Lot Number

VAX LOT Total
2S9CL1,906
1,575
289
IMM209286
252
236
229
s029456178
171
UT7065MA166
155
149
145
S034636133
107
U62828AA103
100
98
P10025327596
U6737AA85
UJ446AA79
78
78
59
57
4BH3254
4F47253
52
27656352
50
PP9L548
49TM346
42
40
38
MENVEO38
4F47237
R1B252M36
34
C5763AA30
93362229
25
300057A24
UNK24
22
CW311621
18
17
15
UH894AB15
3Y7NL12
R1B743M12
EJ168611
el128410
10
10
10
9
ARBA141A9
UNK9
8
UNK8
8
1F4EB8
Unknown7
7
No batch number6
5
5
UJ090AA5
5
5
4
4
4
UNK4
JEV18K95E4
UNK3
A115A3
Z127A3
3
3333324181073
2
2
2
TAR352
1
1
1
1
1
A739081
1
1
1
1
1
037K20A68,542
EL128447,700
133

Incidents per State

State Total
15,185
CA14,096
NY7,507
TX7,196
FL6,939
IN5,527
PA4,560
IL4,179
OH4,054
AZ3,856
MI3,771
NJ3,411
MA3,278
VA3,208
NC3,114
WA3,034
GA2,864
MD2,652
MN2,534
CO2,532
WI2,457
MO2,029
OR1,943
TN1,715
CT1,693
KY1,603
OK1,226
AL1,201
KS1,162
IA1,157
SC1,106
NM1,065
UT973
AR951
LA945
NE829
NV797
ME795
MT789
NH756
ID674
AK661
WV661
PR650
MS585
HI536
RI510
VT441
SD361
ND356
DE350
DC239
WY209
GU32
AS16
VI13
MP9
MH3
FM2
QM1
XB1

ID: 0973095
Sex: U
Age: 12
State: TX

Vax Date: 11/17/2020
Onset Date: 11/17/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: no AE; product experienced multiple temperature excursions and that some of the product might have been administered to patients; This spontaneous report was received from a medical assistant, referring to a 12 years old patient of unknown gender. The patient's historical drugs, medical history, concomitant therapies, drugs allergies and concurrent conditions were not reported. On 17-NOV-2020, the patient was vaccinated with an improperly stored dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0,5 ml, lot # 1637648, expiration date 19-JUN-2022 for prophylaxis (strength, route and frequency were not reported). The reporter said the vaccine experienced multiple temperature excursions and that some of the product might have been administered to patients. The temperature excursion was of -2.09 Centigrade degrees (?C) during 37 hours. A previous temperature excursion occurred of 12.9 ?C for 2 hours.A digital data logger was involved. No other adverse events were reported. This is one of three reports received from the same source. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1637648; expirationdate: 19-JUN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments: US-009507513-2101USA011510: US-009507513-2101USA011511:

Other Meds: GARDASIL 9 SYRINGE (DEVICE)

Current Illness:

ID: 0973096
Sex: U
Age:
State: TX

Vax Date: 01/07/2021
Onset Date: 01/07/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: No other AE reported; incorrect product storage; This spontaneous report was received from a person of physician's office, referring to a patient of unknown age and gender. The patient's historical drugs, medical history, concomitant therapies, drugs allergies and concurrent conditions were not reported. On 07-JAN-2021, the patient was vaccinated with an improperly stored dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0,5 ml, lot # 1602284, expiration date 26-SEP-2021 for prophylaxis (strength, route and frequency were not reported). The temperature excursion was of 31.2 Centigrade degrees (?C) during 30 minutes. A previous temperature excursion was not reported. A digital data logger was involved. No other adverse events were reported. This is one of several reports received from the same source. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1602284; expirationdate: 26-SEP-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Other Meds: GARDASIL 9 SYRINGE (DEVICE)

Current Illness:

ID: 0973098
Sex: U
Age:
State: TX

Vax Date: 01/12/2021
Onset Date: 01/12/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: No other AE reported; report a temperature excursion; This spontaneous report was received from an other type of reporter and refers to a patient of unknown age and gender. No information was given regarding the patient's concurrent conditions, concomitant medications or medical history. On 12-JAN-2021, the patient was vaccinated with an improperly stored dose of pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) lot # T007790 with expiration date on 03-DEC-2021, 0.5 milliliter for prophylaxis (route of administration was not reported). However, no adverse events were reported. This temperature excursion occurred on an unknown date, at a 31.2 F temperature for 30 minutes. There was no previous temperature excursion reported and it was confirmed that a digital data logger was involved. This is one of several reports received from the same source. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T007790; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Other Meds: PNEUMOVAX23 SYRINGE (DEVICE)

Current Illness:

ID: 0973099
Sex: U
Age:
State: OH

Vax Date:
Onset Date: 01/20/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: No additional adverse event; Rotateq was improperly stored and administered; This spontaneous report was received from a nurse regarding a patient of unknown age and gender. The patient's, pertinent medical history, previous drug reactions or allergies, and concomitant therapies were not reported. On 20-JAN-2021, the patient was vaccinated with improperly stored dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) (dose, route of administration, anatomical location and vaccine scheme were not provided), lot number: 1687012 has been verified to be a valid lot number, expiration date was on 08-JUL-2021 as prophylaxis (product storage error). There was no adverse effect reported. Administered dose of vaccine experienced the temperature excursion of 50 Fahrenheit (?F), for a time frame of 1 hour. A digital data logger was involved. There were no previous temperature excursions reported.

Other Meds:

Current Illness:

ID: 0973101
Sex: U
Age: 16
State: TX

Vax Date: 11/18/2020
Onset Date: 11/18/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: no AE; product experienced multiple temperature excursions and that some of the product might have been administered to patients; This spontaneous report was received from a medical assistant, referring to a 16 years old patient of unknown gender. The patient's historical drugs, medical history, concomitant therapies, drugs allergies and concurrent conditions were not reported. On 18-NOV-2020, the patient was vaccinated with an improperly stored dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0,5 ml, lot # 1637648, expiration date 19-JUN-2022 for prophylaxis (strength, route and frequency were not reported). The reporter said the vaccine experienced multiple temperature excursions and that some of the product might have been administered to patients. The temperature excursion was of -2.09 Centigrade degrees (?C) during 37 hours. A previous temperature excursion occurred of 12.9 ?C for 2 hours.A digital data logger was involved. No other adverse events were reported. This is one of three reports received from the same source. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1637648; expirationdate: 19-JUN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments: US-009507513-2101USA011511: US-009507513-2101USA009815:

Other Meds: GARDASIL 9 SYRINGE (DEVICE)

Current Illness:

ID: 0973102
Sex: U
Age: 16
State: TX

Vax Date: 11/18/2020
Onset Date: 11/18/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: no AE; product experienced multiple temperature excursions and that some of the product might have been administered to patients; This spontaneous report was received from a medical assistant, referring to a 16 years old patient of unknown gender. The patient's historical drugs, medical history, concomitant therapies, drugs allergies and concurrent conditions were not reported. On 18-NOV-2020, the patient was vaccinated with an improperly stored dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0,5 ml, lot # 1637648, expiration date 19-JUN-2022 for prophylaxis (strength, route and frequency were not reported). The reporter said the vaccine experienced multiple temperature excursions and that some of the product might have been administered to patients. The temperature excursion was of -2.09 Centigrade degrees (?C) during 37 hours. A previous temperature excursion occurred of 12.9 ?C for 2 hours.A digital data logger was involved. No other adverse events were reported. This is one of three reports received from the same source. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: 1637648; expirationdate: 19-JUN-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments: US-009507513-2101USA009815: US-009507513-2101USA011510:

Other Meds: GARDASIL 9 SYRINGE (DEVICE)

Current Illness:

ID: 0973104
Sex: F
Age: 58
State: MO

Vax Date: 08/01/2018
Onset Date: 10/01/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: her first dose August 2018 / is unsure that she received the second dose; The area was really inflamed; Scar; swelling went down but nothing else changed.; poison ivy; diagnosed her with shingles; This case was reported by a consumer and described the occurrence of shingles in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. In August 2018, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. In October 2020, more than 2 years after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles, inflammation localized, scar, swelling and poison ivy rash. On an unknown date, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the shingles and incomplete course of vaccination were recovered/resolved and the outcome of the inflammation localized, scar, swelling and poison ivy rash were unknown. It was unknown if the reporter considered the shingles, inflammation localized, scar, swelling and poison ivy rash to be related to Shingrix. Additional details were provided as follows: After receiving 1st dose of Shingrix, the patient experienced area on her left leg that started small and grew. The patient went to urgent care and they quickly diagnosed her with shingles. Till the time of reporting patient did not receive 2nd dose of Shingrix which led to incomplete course of vaccination. The patient believes that it could have been poison ivy because she was outside, however, her son had a mild case of chicken pox also. The area was really inflamed so they gave her a steroid shot and the overall swelling went down but nothing else changed. The patient still has a scar. The patient had steroid shot. The patient was unsure that she received the second dose because her HCP has no record of a second shot in their system and she cannot recall getting the second dose. The reporter consent to follow up.

Other Meds:

Current Illness:

ID: 0973105
Sex: F
Age: 50
State: VT

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Pulmonary embolism; Blue lips; Immediately after getting shot she couldn't breath; A spontaneous report was received from a nurse who was also a female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced difficulty breathing, blue lips, shortness of breath, and pulmonary embolism. The patient's medical history included pulmonary embolism. No relevant concomitant medications were reported. On 30 Dec 2020, moments prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot number 026L20A) intramuscularly for prophylaxis of COVID-19 infection. The patient began to feel like she couldn't breathe, and her lips were blue immediately after receiving the vaccine on 30 Dec 2020. The symptoms resolved within an hour. On 05 Jan 2021, she developed shortness of breath and experienced pulmonary embolism. Treatment included apixaban. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the events, difficulty breathing, blue lips, shortness of breath, and pulmonary embolism, were not reported.; Reporter's Comments: This case concerns a female patient, nurse, of unknown age with medical history of Pulmonary embolism, who experienced a serious, unexpected event of difficulty breathing, cyanosis and pulmonary embolism. The event of difficulty breathing and cyanosis occurred immediately and pulmonary embolism occurred after 7 days after first dose of mRNA-1273 (lot number 026L20A). Based on the current available information and temporal association between the use of mRNA-1273 and the start of the event, a causal relationship cannot be excluded.

Other Meds:

Current Illness:

ID: 0973107
Sex: M
Age: 49
State: MA

Vax Date: 12/28/2020
Onset Date: 01/05/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Ear infection; Pain in ear; Inflammation in ear; A spontaneous report was received from a consumer concerning a 49-year old, male patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced pain in ear, inflammation in ear, and ear infection. The patient's medical history was not provided. No relevant concomitant medications were reported. On 28 Dec 2020, eight days prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 intramuscularly in the left arm for prophylaxis of COVID-19 infection. On 05 Jan 2021, the patient began experiencing pain and inflammation in his ear and was treating for an ear infection. Treatment for the event included pseudoephedrine, loratadine, ibuprofen, diphenhydramine hydrochloride, and amoxicillin. Action taken with mRNA-1273 in response to the events was not reported. The outcomes of the events, pain in ear, inflammation in ear, and ear infection, were unknown.; Reporter's Comments: This case concerns a male patient, who experienced a serious unexpected event of ear infection and non-serious unexpected events of ear pain and inner ear inflammation. The event of ear infection, ear pain, inner ear inflammation occurred 9 days after mRNA-1273 (lot # unknown) administration. Treatment included pseudoephedrine, loratadine, ibuprofen, diphenhydramine hydrochloride, and amoxicillin. Based on temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.

Other Meds:

Current Illness:

ID: 0973108
Sex: F
Age:
State:

Vax Date:
Onset Date:
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Bad allergic reaction; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced a bad allergic reaction. The patient's medical history was not provided. No relevant concomitant medications were reported. On an unknown date, prior to the onset of the event, the patient received their first of two planned doses of mRNA-1273 intramuscularly in the arm for prophylaxis of COVID-19 infection. After receiving the vaccine, the patient experienced a bad allergic reaction. Treatment for the event included epinephrine injection. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, experienced a bad allergic reaction, was unknown.; Reporter's Comments: This case concerns a female patient, who experienced a serious unexpected event of hypersensitivity. The event of hypersensitivity occurred on an unspecified date after first dose of mRNA-1273, lot # unknown. She was treated with EpiPen. Very limited information regarding this event has been provided at this time. Based on the current available information and temporal association between the use of the product and onset of the event, a causal relationship cannot be excluded.

Other Meds:

Current Illness:

ID: 0973109
Sex: F
Age: 50
State: MS

Vax Date: 01/07/2021
Onset Date: 01/07/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20210107; Test Name: Oxygen saturation; Test Result: 82 %

Allergies:

Symptoms: Anaphylactic response; A spontaneous report was received from a consumer who was a 50-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced an anaphylactic response. The patient's medical history was not provided. No relevant concomitant medications were reported. On 07 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 intramuscularly in the left arm for prophylaxis of COVID-19 infection. On 07 Jan 2021, a few minutes after receiving the vaccine, the patient experienced an anaphylactic response. Her extremities went cold, her mouth was dry, and she couldn't swallow due to her throat being swollen. She was given intravenous fluids and oxygen due to her oxygen saturation being 82 percent. She was also given an epinephrine injection and was taken to the emergency room to be observed for a few hours. Action taken with mRNA-1273 in response to the events was not provided. The outcome of the event, anaphylactic response, was unknown.; Reporter's Comments: This case concerns a 50-year-old female patient, who experienced a serious unexpected event of Anaphylactic reaction. The event occurred soon after first dose of the study medication administration. The patient was treated with an Epi-pen, Benadryl iv, and oxygen. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded

Other Meds:

Current Illness:

ID: 0973111
Sex: M
Age: 76
State: MD

Vax Date: 12/30/2020
Onset Date: 12/31/2020
Rec V Date: 01/26/2021
Hospital: Y

Lab Data: Test Date: 20201231; Test Name: Body temperature; Test Result: 100 {DF}; Test Date: 20201231; Test Name: EKG; Result Unstructured Data: Normal; Test Date: 20210105; Test Name: EKG; Result Unstructured Data: A-Fib; Test Date: 20201231; Test Name: COVID-19 rapid POC test; Result Unstructured Data: Negative

Allergies:

Symptoms: Mild Chest Pain Worse With Deep Breath/chest pain got worse; Felt warm and his temperature was 100 F; Now I have A-Fib; A spontaneous report was received from a consumer concerning a male 76-year-old patient, who was also the patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced chest pain, fever, and atrial fibrillation. The patient's medical history, as provided by the reporter, included coronary artery disease. Concomitant medications included carvedilol. On 30 Dec 2020, the patient received their first of two planned doses of mRNA-1273 in the right deltoid for prophylaxis of COVID-19 infection. On 31 Dec 2020, the patient experienced chest pain that got worse when he took a deep breath. He also felt warm, and his temperature was 100 degrees Fahrenheit. The patient visited the emergency room where an electrocardiogram (EKG) was normal and his COVID-19 test were negative. Because of his history of coronary artery disease, he stayed in the hospital overnight. On 01 Jan 2021, the hospital cardiologist called it a reaction the vaccine, and he was discharged. On 05 Jan 2021, on a follow-up visit with another cardiologist, another EKG was performed, and the patient was diagnosed with atrial fibrillation. The cardiologist increased his carvedilol dose to 6.25 milligram from 3.125 milligram and added apixaban, 5 milligram, twice daily. At the time of the report, he felt fine. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the events, chest pain and fever, was considered recovered/resolved on 01 Jan 2021. The outcome of the event, atrial fibrillation, was considered recovering/resolving.; Reporter's Comments: This case concerns a 76-year-old male patient with medical history of coronary artery disease, who received their first of two planned doses of mRNA-1273 (Lot unknown), and who experienced the serious unlisted events of chest pain and atrial fibrillation and the non-serious listed event of fever. Based on the current available information and temporal association between the use of the product and the onset of events, a causal relationship cannot be excluded and the events are considered possibly related to the vaccine. However, the events of chest pain and atrial fibrillation may be explained by the patient's history of coronary artery disease.

Other Meds: COREG

Current Illness:

ID: 0973112
Sex: F
Age: 34
State:

Vax Date: 01/09/2021
Onset Date: 01/09/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Anaphylaxis; A spontaneous report was received from a consumer concerning a 34-years-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced anaphylaxis. The patient's medical history was not provided. No relevant concomitant medications were reported. On 09 Jan 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 026L20A) intramuscularly in the right arm for COVID-19 infection prophylaxis. On 09 Jan 2021, 15 minutes after receiving the mRNA-1273 vaccination, the patient was taken to the hospital for anaphylaxis. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of event, anaphylaxis, was unknown.; Reporter's Comments: This case concerns a patient who experienced a serious unexpected event of Anaphylaxis. The event occurred 1 day after first dose of mRNA-1273. Very limited information regarding this event has been provided at this time. Based on temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.

Other Meds:

Current Illness:

ID: 0973114
Sex: F
Age:
State: NY

Vax Date: 01/09/2021
Onset Date: 01/10/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Hurts when she breathes; Unable to lift arm; On and off chest pain; Spasms; Fast heartbeat; Did not feel good; Headache; Vomiting; A spontaneous report was received from a consumer regarding a female patient who received Moderna's COVID-19 Vaccine (mRNA-1273), and experienced the events, did not feel good, headache, vomiting, chest pain, spasms, a fast heartbeat, unable to lift arm, and hurts when she breathes. The patient's medical history was not provided. Concomitant medications were not provided by the reporter. On 09 Jan 2021, approximately 24 hours prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On 10 Jan 2021, the patient did not feel well and experienced a headache and vomiting. On 11 Jan 2021, the patient experienced on and off chest pain, spasms, and a fast heart beat. She was unable to lift her arm and it hurt when she would breathe. An emergency medical technician (EMT) was called to assist the patient. No further details were provided. Treatment for the events was not provided. Action taken with mRNA-1273 in response to the events was unknown. The outcome of the events, did not feel good, headache, vomiting, chest pain, spasms, a fast heartbeat, unable to lift arm, and hurts when she breathes, was not reported.; Reporter's Comments: This case concerns a female patient, who experienced serious unexpected events of painful breathing, and non-serious unexpected event of vaccination site movement impairment, chest pain, muscle spasm, malaise, and heart rate increased; and non-serious expected events of headache and vomiting. The event of malaise, headache and vomiting occurred 2 days after mRNA-1273 (lot # unknown) administration. The event of painful breathing, vaccination site movement impairment, chest pain, muscle spasms, heart rate increased, occurred day 3 after mRNA-1273 (lot # unknown) administration. Treatment details were not provided. Very limited information regarding this event has been provided at this time. Based on temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.

Other Meds:

Current Illness:

ID: 0973115
Sex: F
Age: 48
State: NH

Vax Date: 12/22/2020
Onset Date: 12/22/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20201228; Test Name: Blood pressure; Test Date: 20201229; Test Name: Blood pressure

Allergies:

Symptoms: I felt very tired, I was exhausted; White as a ghost; itching at the injection site; Injection site was hard/hard in the middle/injection site hardness would come and go; Arm was red at the injection site 4x4 inches/injection site redness would come and go; injection site swollen; Headache; Lungs started feeling congested; Felt like my throat spasmed and felt like it wanted to close up; A spontaneous report was received from a licensed nursing assistant concerning a 48-year old, female patient who received Moderna's COVID-19 vaccine and experienced throat spasms, lung congestion, headache, injection site itching, injection site redness, injection site hardness, injection site swelling, fatigue, and pallor. The patient's medical history, as provided by the reporter, included asthma, eczema, and penicillin allergy. No relevant concomitant medications were reported. On 22 Dec 2020, prior to the onset of events, the patient received their first of two planned doses of mRNA-1273 (039K20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection. On 22 Dec 2020, the patient experienced throat spasms about 8 minutes after administration of the vaccine. The patient described the feeling as "feeling like it wanted to close up". She was given water. After 19 minutes, her throat relaxed. That evening, her lungs felt congested, and she had a headache. Treatment included ibuprofen. On 23 Dec 2020, upon awakening, the congestion and headache were better. On 28 Dec 2020, the injection site began itching, was hard in the middle, and red (approximately 4x4 inch area and increasing in size by the end of the day). She was checked in to emergency room and given prednisone for injection site symptoms. Her blood pressure reading was 150/90 which, according to the patient, was a little higher than normal. On 29 Dec 2020, the patient woke up feeling very tired and exhausted. Her nurses said she looked "white as a ghost". She was given orange juice and crackers and felt like she had more energy. She returned to work. The injection site redness and hardness would come and go. On 01 Jan 2021, the patient described the injection site as looking "like a tick bite". The site was still hard and red. On 02 Jan 2021, treatment included clindamycin. On 04 Jan 2021, the redness went away. On 08 Jan 2021, she completed the antibiotic and all events were resolved. Action taken with mRNA-1273 in response to the events was not reported. The event, throat spasms, was considered recovered/resolved on 22 Dec 2020. The events, lung congestion and headache, were considered recovered/resolved on 23 Dec 2020. The event, injection site redness, was considered resolved on 04 Jan 2021. The events, injection site itching, injection site hardness, injection site swelling, fatigue, and pallor, were considered recovered/resolved on 08 Jan 2021.; Reporter's Comments: This case concerns a 48 year old female patient with medical history asthma, penicillin allergy among others. The patient was administered the first and only dose of the mRNA-1273 (lot # 039K20A) (expiration date unknown) and experienced serious unexpected event of pulmonary congestion on the same day after administration and non-serious events of headache occurred on the same day mRNA-1273 administration, oropharyngeal spasm occurred 8 minutes after mRNA-1273 administration , injection site hardness, injection site pruritus', injection site redness, injection site swelling and fatigue occurred 7 days after mRNA-1273 administration and pallor occurred 8 days after mRNA-1273 administration,.De-challenge and re-challenge. Based on temporal association between the use of the product and the start date of the event of pulmonary congestion and laryngospasm, and on the known safety profile for mRNA-1273 for the other reported r non-serious events, a causal relationship cannot be excluded. Hence events are assessed as possibly related to the administration of mRNA-1273 vaccine

Other Meds:

Current Illness: Asthma; Eczema; Penicillin allergy

ID: 0973117
Sex: F
Age:
State:

Vax Date:
Onset Date:
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Cellultic response 8 days after receiving the COVID vaccine; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the event, cellulitis. The patient's medical history was not provided. Concomitant medication use was not provided by the reporter. On an unknown date, the patient received the first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On an unknown date, the patient developed cellulitis 8 days after receiving the vaccine. No treatment information was provided. Action taken with mRNA-1273 in response to the event was not reported. The outcome of the event, cellulitis, is considered unknown.; Reporter's Comments: This case concerns a female patient who received their first of two planned doses of mRNA-1273 (Lot unknown), and who experienced the serious unlisted event of cellulitis. Very limited information regarding this event has been provided at this time. Based on the current available information and temporal association between the use of the product and the onset of the event 8 days after vaccination, a causal relationship cannot be excluded and the event is considered possibly related to the vaccine.

Other Meds:

Current Illness:

ID: 0973118
Sex: F
Age:
State: OH

Vax Date: 01/09/2021
Onset Date:
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Anaphylactic Reaction; Significant angioedema; Severe allergic reaction; A spontaneous report was received from a nurse, who was also a 28-year old, female patient who received Moderna's COVID-19 vaccine and experienced an anaphylactic reaction, a severe allergic reaction, and significant angioedema. The patient's medical history, as provided by the reporter, included Hashimoto's disease and thyroid disease. No relevant concomitant medications were reported. On 09 Jan 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 039K20-2A) intramuscularly for prophylaxis of COVID-19 infection. On an unknown date, the patient experienced an anaphylactic reaction, significant angioedema and a severe allergic reaction. Treatment for the events included epinephrine, unspecified antihistamines and unspecified intravenous fluids. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the events was considered not resolved.; Reporter's Comments: This case concerns a 28 year old, female patient with medical history of autoimmune disorders including Hashimotos disease and thyroid disease, who experienced a serious unexpected event of anaphylactic reaction, angioedema and hypersensitivity reaction. The event occurred on an unspecified date after first dose mRNA-1273 ((Lot# 039K20-2A) administration. The subject's concomitant medication was not provided. The event was treated with epinephrine, iv fluids and anti-histamines. Based on temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.

Other Meds:

Current Illness: Hashimoto's disease; Thyroid disorder

ID: 0973132
Sex: F
Age: 71
State: GA

Vax Date: 01/01/2021
Onset Date: 01/25/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Fever

Other Meds: Tylenol

Current Illness:

ID: 0973133
Sex: F
Age: 64
State: CO

Vax Date: 01/16/2021
Onset Date: 01/25/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: None

Allergies: Morphine, Tramadol, Percocet, Percodan, Ceclor, Amoxicillin, ibuprofen, adhesive, Tamsulosin, Biaxin

Symptoms: Rash at injection site appeared 9 days after injection 1.5? x 2?

Other Meds: Gabapentin Pantoprozale Breztri inhaler Estrogel Clotrimazole

Current Illness: Newly diagnosed with asthma and atelectasis in both lower lobes of lungs

ID: 0973134
Sex: F
Age: 41
State: MN

Vax Date: 01/20/2021
Onset Date: 01/20/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: None

Allergies: Nickle

Symptoms: Hives, itching, tongue swelling

Other Meds: Allegra

Current Illness: Eczema flare up

ID: 0973135
Sex: F
Age: 49
State: CA

Vax Date: 01/21/2021
Onset Date: 01/21/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Tingling in extremity after 10 minutes of administering vaccine. Jaw tightness, dizziness, nausea and chills for two days. Occasional low grad fever for two days. Fatigue for 5 days.

Other Meds: Levoxyl, Vit D, CQ10,

Current Illness:

ID: 0973136
Sex: F
Age: 72
State:

Vax Date: 01/18/2021
Onset Date: 01/20/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Experiencing vision blurriness, dry eyes, - utilizes eye drops and resolves. Feels "heavy" some sneezing too.

Other Meds:

Current Illness:

ID: 0973137
Sex: F
Age:
State: PA

Vax Date: 12/30/2020
Onset Date: 01/13/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20210113; Test Name: COVID virus; Test Result: Positive

Allergies:

Symptoms: but tested covid positive; but tested covid positive; had sinus; a little diarrhea; cough; The initial case was missing the following minimum criteria: No adverse effect. Upon receipt of follow-up information on 13Jan2021, this case now contains all required information to be considered valid. This is a spontaneous report from a contactable consumer, reporting for herself. A 67-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EJ1685), via an unspecified route of administration at the right arm at on 30Dec2020 11:15 at a single dose as the patient works for a medical retirement facility. Vaccination was done in a hospital. Medical history included was reported as none. The patient's concomitant medications were not reported. It was reported that the patient got her first shot on 30Dec2020, but tested COVID positive on 13Jan2021, had sinus, a little diarrhea, and cough. She was on quarantine with her husband as of today. She did not receive any other vaccines that day or 4 weeks prior. No history of any other vaccines or events. She was asking if she can take the second dose of the COVID vaccine. The patient underwent lab tests and procedures which included COVID virus: positive on 13Jan2021. The outcome of the events was unknown.

Other Meds:

Current Illness:

ID: 0973138
Sex: F
Age: 44
State: CA

Vax Date: 01/15/2021
Onset Date: 01/23/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: NA

Allergies: Yes, but unknown. Had to go to ER in the past for epi

Symptoms: 8 days after vaccination, a slightly elevated circular redness on left deltoid noticed around 730pm. Sunday morning upon wakening, notice the circle has taken more off an irregular shaped oval. Monday morning, the area has turned into a reddish and pronounced rectangular shape. Asymptomatic, but area is warm to touch.

Other Meds: Generic Zyrtec

Current Illness: NA

ID: 0973139
Sex: M
Age: 44
State:

Vax Date: 01/18/2021
Onset Date: 01/19/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Injection site pain, headache, muscle aches, "cottony" taste, congestion, slightly runny first thing in am

Other Meds:

Current Illness:

ID: 0973140
Sex: F
Age: 44
State: CA

Vax Date: 01/23/2021
Onset Date: 01/25/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: none

Allergies: penicillin (says mother)

Symptoms: scattered rash on chest and upper abdomen, asymptomatic

Other Meds: allegra, birth control

Current Illness: none noted

ID: 0973141
Sex: F
Age: 68
State:

Vax Date: 01/16/2021
Onset Date: 01/17/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: None

Allergies: Alendronate, bee stings, carrots, erythromycin, NSAIDs, Penicillins, Zoledronic acid, Zolpidem

Symptoms: "extremely fatigue" and "feeling high".

Other Meds: Arnica topical Calcium and vitamin d famotidine Loratadine ferrous sulfate flax oil Bone solid Echinacea Ginko Biloba PB8 Probiotic Red Colver Sam E Tumeric w Bioperine Stronti Bromium-89 Chloride Quercetin with Bromelain

Current Illness: None

ID: 0973142
Sex: M
Age:
State:

Vax Date: 01/02/2020
Onset Date: 01/01/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: fever; The initial case was missing the following minimum criteria: no adverse event. Upon receipt of follow-up information on 12Jan2021, this case now contains all required information to be considered valid. This is a spontaneous report from a Pfizer-sponsored program, from a contactable physician (patient). A male patient of unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via unspecified route single dose for COVID-19 immunization on 02Jan2020. Medical history and concomitant medication were not reported. The patient received his first dose of BNT162B2 and experienced side effects afterwards. He started coming down with a fever took paracetamol (TYLENOL) to help with the fever (from Jan2021). Action taken for BNT162B2 was not applicable. Outcome of the event was unknown. Information on the lot/batch number has been requested.

Other Meds:

Current Illness:

ID: 0973143
Sex: F
Age: 29
State: ID

Vax Date: 01/20/2021
Onset Date: 01/21/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: none

Allergies: none

Symptoms: Mild Fever (99.6 F), severe headache, hot flashes, chills, fatigue. Started the morning following the vaccination, continued for approximately 24 hours. Spent the whole day in bed.

Other Meds: none

Current Illness: none

ID: 0973144
Sex: F
Age: 36
State: AZ

Vax Date: 01/12/2021
Onset Date: 01/13/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: US and CT normal. WBC low at 3.8 with a shift.

Allergies: Biaxin and Tubersol

Symptoms: Right sided jaw to chest pain. Right sided chest pain was intermittent and became severe enough to go into ER.

Other Meds: melatonin and doxylamine

Current Illness: none

ID: 0973145
Sex: F
Age: 51
State: CA

Vax Date: 01/16/2021
Onset Date: 01/17/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: none

Allergies: Tetracyclene

Symptoms: Red bumps on lower legs (possibly Poiser Oak)-- itchy, noticed when I awoke day after vaccine vaginal yeast infection (noticed 2 days after vaccine and still have) irritated stomach/colon

Other Meds: Vitamin D

Current Illness: none

ID: 0973146
Sex: F
Age: 31
State:

Vax Date: 01/19/2021
Onset Date: 01/20/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Temp 101, then 100, joint pain, headaches and chills

Other Meds:

Current Illness:

ID: 0973147
Sex: M
Age: 57
State: TX

Vax Date: 01/16/2021
Onset Date: 01/24/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies: Penicillin, cat dander, cut grass

Symptoms: Started to experience slight swelling and itching at injection site on day 8 after vaccination. 4-5 cm area around injection site is warm to touch and flushed. Level of itching is about the same as a mosquito bite. Swelling is a 1-1.5 cm bump at injection site.

Other Meds: Niacin, Vitamin C, Vitamin D3, Echinacea, Adult multivitamin

Current Illness: n/a

ID: 0973148
Sex: F
Age: 57
State: OR

Vax Date: 01/22/2021
Onset Date: 01/22/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies: Sulfa drugs

Symptoms: Extreme muscle aches, rate 9 on scale of 1 to 10.

Other Meds: None

Current Illness: None

ID: 0973149
Sex: F
Age: 82
State: NC

Vax Date: 01/12/2021
Onset Date: 01/25/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: 1 week after vaccination, started itching on the site, next day developed rash around the vaccination site with itching. Next day developed a very pink place below the site about two inches in diameter and also itched. This continued for 4 days. On 1/25/21 the itch is gone and the rash and pink spot are fading.

Other Meds:

Current Illness:

ID: 0973150
Sex: M
Age: 61
State: CA

Vax Date: 01/20/2021
Onset Date: 01/21/2021
Rec V Date: 01/26/2021
Hospital: Y

Lab Data:

Allergies: nkda

Symptoms: Pt had slurred speech and left-sided weakness day after vaccine he presented to ER and appears to have CVA

Other Meds: lipitor asa glipizide coreg losartan

Current Illness:

ID: 0973151
Sex: M
Age: 29
State: NY

Vax Date: 01/20/2021
Onset Date: 01/21/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: none

Allergies: seasonal

Symptoms: fever, rigor, headache, body ache 6 days post vaccination

Other Meds: multi-vitamin

Current Illness: none

ID: 0973152
Sex: F
Age: 41
State:

Vax Date: 01/12/2021
Onset Date: 01/13/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Severe headache, muscle and body aches

Other Meds:

Current Illness:

ID: 0973153
Sex: M
Age: 29
State: CA

Vax Date: 01/11/2021
Onset Date: 01/15/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: A red rash on injection arm that has not gone away and a red rash that showed up on my neck, back and chest that comes and goes.

Other Meds:

Current Illness:

ID: 0973154
Sex: F
Age: 29
State: NY

Vax Date: 01/17/2021
Onset Date: 01/25/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies: Cefzil

Symptoms: Cellulitis-like patch couple an inch or so below injection site. Warm, taut, and red puffy skin

Other Meds: Adderall, bupropion

Current Illness:

ID: 0973155
Sex: M
Age:
State: MI

Vax Date: 01/04/2021
Onset Date: 01/10/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20210110; Test Name: fever; Result Unstructured Data: Test Result:highest was 100.3; Test Date: 20210110; Test Name: rapid and standard test; Test Result: Positive

Allergies:

Symptoms: tested positive both with a rapid and standard test; tested positive both with a rapid and standard test; This is a spontaneous report from contactable consumer. A 92-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot/batch number unknown), via an unspecified route of administration on 04Jan2021 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient who was in a nursing home received the vaccine first dose on 04Jan2021. On 10Jan2021, he tested positive both with a rapid and standard test. His fever at the highest was 100.3 and he had chills and a cough but that's all gone now. Thought maybe it's because he received the vaccine. The outcome of the events was unknown. Information on the lot/batch number has been requested.

Other Meds:

Current Illness:

ID: 0973156
Sex: F
Age:
State:

Vax Date: 12/01/2020
Onset Date: 12/15/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20201215; Test Name: tested positive for COVID; Test Result: Positive

Allergies:

Symptoms: received the 1st dose on 01Dec2020 and tested positive for COVID on 15Dec2020 but was asymptomatic.; received the 1st dose on 01Dec2020 and tested positive for COVID on 15Dec2020 but was asymptomatic.; This is a spontaneous report from a contactable other healthcare professional reported that a female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 01Dec2020 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The reporter was asking what the recommendations are for the administration of the 2nd dose for a patient who received the 1st dose on 01Dec2020 and tested positive for COVID on 15Dec2020 but was asymptomatic. She missed the dosing window of the 2nd dose scheduled on 30Dec2020 due to quarantine. Caller mentioned that patient is recovered and is back to work. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on 15Dec2020. Information about lot/batch number has been requested; Sender's Comments: Based on available information, a possible contributory role of the subject product, BNT162B2 vaccine, cannot be excluded for the reported events of COVID-19 and suspected LOE due to temporal relationship. There is limited information provided in this report. Additional information is needed to better assess the case, including complete medical history, diagnostics, counteractive treatment measures and concomitant medications. This case will be reassessed once additional information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.

Other Meds:

Current Illness:

ID: 0973157
Sex: F
Age: 39
State: MA

Vax Date: 01/20/2021
Onset Date: 01/21/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: n/a

Allergies: none

Symptoms: lethargic, headache, generalized body ache , arm weakness, arm pain swollen and painful

Other Meds: nexium

Current Illness: none

ID: 0973158
Sex: F
Age:
State: OH

Vax Date: 01/11/2021
Onset Date: 01/12/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20210104; Test Name: Bloodwork; Result Unstructured Data: Test Result:Unknown result

Allergies:

Symptoms: cramping; Diarrhea; body aches; Headache; Nausea; Vomiting; This is a spontaneous report from a contactable consumer (patient) and another consumer. A 46-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231, expiration date: 30Apr2021), intramuscular (right arm) on 11Jan2021 (around 1:10-1:30pm) at single dose for Covid-19 immunization. The patient received the first dose of COVID Vaccine (BNT162B2, lot number: EK5730, expiration date: 31Mar2021) on 21Dec2020, intramuscular (right arm) for Covid-19 immunization. There were no medical history and concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 12Jan2021, the patient experienced nausea, some vomiting which has subsided, diarrhea, headache and body aches. The patient also stated that she woke up at 3 a.m. this morning (12Jan2021) vomiting. She vomited for about an hour and half. The vomiting has subsided and now she is just nauseated. The diarrhea initially began about 7:30 a.m. She had 3 bowel movements and she hasn't had a movement since about 8:30. She still has cramping but nothing else. The body aches started within last half hour or so. The headache has been the entire time since 3 a.m., starting when the vomiting occurred. The vomiting was more important at that moment, but she knows her head hurting at the time. The patient verified it was her second COVID vaccine. She received the vaccine yesterday (11Jan2021), between 1:10-1:30p.m. The patient reported that she did have bloodwork, but not in regard to the COVID vaccine. She had bloodwork done Monday, 04Jan2021. The outcome of vomiting was recovering; outcome of event cramping was unknown; while the outcome of other events was not recovered.

Other Meds:

Current Illness:

ID: 0973159
Sex: F
Age: 72
State:

Vax Date: 01/18/2021
Onset Date: 01/22/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Experiencing vision blurriness, dry eyes, - utilizes eye drops and resolves. Feels "heavy" some sneezing too.

Other Meds:

Current Illness:

ID: 0973160
Sex: F
Age:
State: OH

Vax Date: 01/04/2021
Onset Date: 01/08/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20210108; Test Name: COVID; Test Result: Positive

Allergies:

Symptoms: "symptoms"/tested positive for covid; "symptoms"/tested positive for covid; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age (reported as 76 with no unit) received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number and expiry date unknown), via an unspecified route of administration on 04Jan2021 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient was asking if she should get her second dose of vaccine on 25Jan2021, after receiving the first dose on 04Jan2021 and having symptoms and testing positive for COVID on 08Jan2021. The patient continued to have symptoms (unspecified) at the time of report. The patient was taking Tylenol for the symptoms. Outcome of the events was not recovered. Information about lot/batch number has been requested.

Other Meds:

Current Illness:

ID: 0973161
Sex: F
Age:
State: PA

Vax Date: 12/30/2020
Onset Date: 12/30/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 202012; Test Name: COVID test; Test Result: Negative

Allergies:

Symptoms: axillary was tender and occasionally painful; 50 cent size lump on the side of her arm at injection site that was raised, warm, red, and tender at the injection site; 50 cent size lump on the side of her arm at injection site that was raised, warm, red, and tender at the injection site; 50 cent size lump on the side of her arm at injection site that was raised, warm, red, and tender at the injection site; 50 cent size lump on the side of her arm at injection site that was raised, warm, red, and tender at the injection site; patient received the covid vaccine on the 30Dec had a sore arm; This is a spontaneous report from a contactable pharmacist. A 54-year-old female patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiry date not reported), via an unspecified route of administration on 30Dec2020 at single dose on the arm for COVID-19 immunization. The patient medical history included "had classic symptoms of COVID, but had a negative COVID test" on Dec2020. Concomitant medications were not reported. The patient previously had a Tetanus vaccine 23 years ago. After receiving patient spiked a fever 101 and cellulitis at the site. Reporter explained she is not 100 percent sure. She is not sure if the nurse used the DTap abbreviation and truly administered the Tetanus shot. Reporter indicated she is not sure which preparation patient got. Patient received the vaccine on 30Dec2020 and her arm was sore that day when went to bed. The next morning (31Dec2020) the site was tender. She then noticed a nickel size (as reported) red lump that had disappeared on 03Jan2021 (The next day she had tenderness and redness that went away after two days). Patient noticed the 50 cent size (as reported) lump on the side of her arm at injection site that was raised, warm, red, and tender at the injection site the morning of 31Dec2020, an exact time was not specified. On 07Jan2021 he had a 50 cent size lump on the side of her arm at injection site in arm received injection that was raised, warm, red, and tender at the injection site. On 07Jan2021 her axillary was tender and occasionally painful. On 08Jan2021 it returned to injection site at 1. That day at 6:30 PM on 08Jan2021 she had an area she had a 50 cent size area that was raised, red, and warm. She took Benadryl the next day. The morning of 09Jan2021 she woke up and had more redness tenderness in her arm, therefore, she called her doctor. Her doctor ordered an antibiotic. On 11Jan2021 they entered in the follow-up notes she had slow improvement even though the axillary area is still painful. Reporter explained it sounds like events are slowly improving, they are not completely resolved. Reporter stated it is so weird that the sore arm went away, disappeared, and then came back again. The final outcome of the events was recovering. The adverse events di not require a visit to the emergency room or physician office. The events were as assessed as non-serious by reporter. The causality of events was considered as related by reporter. Information on the Lot/Batch number has been requested.

Other Meds:

Current Illness:

ID: 0973162
Sex: F
Age: 48
State: UT

Vax Date: 01/16/2021
Onset Date: 01/25/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies: Latex Asparin Propofol

Symptoms: Moderna COVID-19 Vaccine EUA Red, itchy, hot rash at injection site 9 days after the vaccine was given.

Other Meds: Metformin 1000mg Hydrochlorathiazide 25mg Selenium 200mg Multivitamin

Current Illness:

ID: 0973163
Sex: F
Age:
State: MN

Vax Date: 12/22/2020
Onset Date: 12/23/2020
Rec V Date: 01/26/2021
Hospital:

Lab Data:

Allergies:

Symptoms: Chills, low grade fever, body aches, headache " brain fog"; Chills, low grade fever, body aches, headache " brain fog"; Chills, low grade fever, body aches, headache " brain fog"; Chills, low grade fever, body aches, headache " brain fog"; Chills, low grade fever, body aches, headache " brain fog"; This is a spontaneous report from a contactable other healthcare professional. A 44-year-old female patient received (not pregnant) her first dose of bnt162b2 (BNT162B2 also reported as Covid 19brand Pfizer BioNTech, lot EJ1685), intramuscular in the left arm 22Dec2020 10:00 at SINGLE DOSE for Covid-19 immunisation. She received the vaccine in a hospital. Medical history included covid prior vaccination: Yes. No other vaccine in four weeks. The patient's concomitant medications were not reported. The patient experienced chills, low grade fever, body aches, headache " brain fog" on 23Dec2020 01:00. No treatment was given. The outcome of events was recovered. No follow-up attempts are possible. No further information is expected.

Other Meds:

Current Illness:

ID: 0973164
Sex: F
Age:
State: UT

Vax Date: 01/09/2021
Onset Date: 01/09/2021
Rec V Date: 01/26/2021
Hospital:

Lab Data: Test Date: 20210109; Test Name: Fever; Result Unstructured Data: Test Result:102.2

Allergies:

Symptoms: Pulsating headaches; Blurry vision; nausea; 102.2 fever; body aches; hand tremors; dizziness; joint pain; Cough; feeling of exhaustion; This is a spontaneous report from a contactable consumer (patient). A 59-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3248), via an unspecified route of administration (right arm) on 09Jan2021 11:00 at single dose for Covid-19 immunization. Medical history included asthma and hypertension. The patient received an unspecified medication in two weeks. The patient previously took codeine and experienced allergy. The patient was not diagnosed with COVID-19 prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient experienced pulsating headaches, blurry vision, nausea, 102.2 fever, body aches, hand tremors, dizziness, joint pain, cough, and feeling of exhaustion on 09Jan2021 (12:00 PM). There was no treatment received for the events. The outcome of events was recovering. The patient has not been tested for COVID-19 since the vaccination.

Other Meds:

Current Illness:

Total 2021 VAERS Injuries: 134,999

Page last modified: 14 December 2021 10:42pm